306 related articles for article (PubMed ID: 18829508)
1. A phase I-II study of docetaxel and atrasentan in men with castration-resistant metastatic prostate cancer.
Armstrong AJ; Creel P; Turnbull J; Moore C; Jaffe TA; Haley S; Petros W; Yenser S; Gockerman JP; Sleep D; Hurwitz H; George DJ
Clin Cancer Res; 2008 Oct; 14(19):6270-6. PubMed ID: 18829508
[TBL] [Abstract][Full Text] [Related]
2. Ixabepilone, mitoxantrone, and prednisone for metastatic castration-resistant prostate cancer after docetaxel-based therapy: a phase 2 study of the Department Of Defense Prostate Cancer Clinical Trials Consortium.
Harzstark AL; Rosenberg JE; Weinberg VK; Sharib J; Ryan CJ; Smith DC; Pagliaro LC; Beer TM; Liu G; Small EJ
Cancer; 2011 Jun; 117(11):2419-25. PubMed ID: 24048789
[TBL] [Abstract][Full Text] [Related]
3. Phase I study of sorafenib in combination with docetaxel and prednisone in chemo-naïve patients with metastatic castration-resistant prostate cancer.
Mardjuadi F; Medioni J; Kerger J; D'Hondt L; Canon JL; Duck L; Musuamba F; Oudard S; Clausse M; Moxhon A; Machiels JP
Cancer Chemother Pharmacol; 2012 Aug; 70(2):293-303. PubMed ID: 22752248
[TBL] [Abstract][Full Text] [Related]
4. Platelet-derived growth factor receptor inhibitor imatinib mesylate and docetaxel: a modular phase I trial in androgen-independent prostate cancer.
Mathew P; Thall PF; Jones D; Perez C; Bucana C; Troncoso P; Kim SJ; Fidler IJ; Logothetis C
J Clin Oncol; 2004 Aug; 22(16):3323-9. PubMed ID: 15310776
[TBL] [Abstract][Full Text] [Related]
5. No additional benefit of adding ifosfamide to docetaxel in castration-resistant metastatic prostate cancer.
Hervonen P; Tulijoki T; Kellokumpu-Lehtinen P
Anticancer Res; 2012 Aug; 32(8):3305-9. PubMed ID: 22843906
[TBL] [Abstract][Full Text] [Related]
6. A phase I study of estramustine, weekly docetaxel, and carboplatin chemotherapy in patients with hormone-refractory prostate cancer.
Oh WK; Hagmann E; Manola J; George DJ; Gilligan TD; Jacobson JO; Smith MR; Kaufman DS; Kantoff PW
Clin Cancer Res; 2005 Jan; 11(1):284-9. PubMed ID: 15671557
[TBL] [Abstract][Full Text] [Related]
7. Phase III, randomized, placebo-controlled study of docetaxel in combination with zibotentan in patients with metastatic castration-resistant prostate cancer.
Fizazi K; Higano CS; Nelson JB; Gleave M; Miller K; Morris T; Nathan FE; McIntosh S; Pemberton K; Moul JW
J Clin Oncol; 2013 May; 31(14):1740-7. PubMed ID: 23569308
[TBL] [Abstract][Full Text] [Related]
8. Multicenter randomized phase II study of two schedules of docetaxel, estramustine, and prednisone versus mitoxantrone plus prednisone in patients with metastatic hormone-refractory prostate cancer.
Oudard S; Banu E; Beuzeboc P; Voog E; Dourthe LM; Hardy-Bessard AC; Linassier C; Scotté F; Banu A; Coscas Y; Guinet F; Poupon MF; Andrieu JM
J Clin Oncol; 2005 May; 23(15):3343-51. PubMed ID: 15738542
[TBL] [Abstract][Full Text] [Related]
9. Prostate-specific antigen response to deferred combined androgen blockade therapy using bicalutamide predicts survival after subsequent oestrogen and docetaxel therapies in patients with castration-resistant prostate cancer.
Kijima T; Fujii Y; Yokoyama M; Ishioka J; Matsuoka Y; Numao N; Saito K; Koga F; Masuda H; Kawakami S; Kihara K
BJU Int; 2012 Oct; 110(8):1149-55. PubMed ID: 22369348
[TBL] [Abstract][Full Text] [Related]
10. A phase 2 study of carboplatin plus docetaxel in men with metastatic hormone-refractory prostate cancer who are refractory to docetaxel.
Ross RW; Beer TM; Jacobus S; Bubley GJ; Taplin ME; Ryan CW; Huang J; Oh WK;
Cancer; 2008 Feb; 112(3):521-6. PubMed ID: 18085595
[TBL] [Abstract][Full Text] [Related]
11. Combination chemotherapy with docetaxel, vinorelbine and estramustine phosphate in metastatic androgen-resistant prostate cancer: a single institution experience.
Pectasides D; Pectasides E; Papaxoinis G; Koumarianou A; Psyrri A; Xiros N; Tountas N; Kamposioras K; Papatsibas G; Floros T; Gouveris P; Karageorgopoulou S; Economopoulos T
Anticancer Res; 2009 Feb; 29(2):769-75. PubMed ID: 19331234
[TBL] [Abstract][Full Text] [Related]
12. Phase II trial evaluating a docetaxel-capecitabine combination as treatment for hormone-refractory prostate cancer.
Ferrero JM; Chamorey E; Oudard S; Dides S; Lesbats G; Cavaglione G; Nouyrigat P; Foa C; Kaphan R
Cancer; 2006 Aug; 107(4):738-45. PubMed ID: 16826591
[TBL] [Abstract][Full Text] [Related]
13. Prospective randomized study comparing docetaxel, estramustine, and prednisone with docetaxel and prednisone in metastatic hormone-refractory prostate cancer.
Machiels JP; Mazzeo F; Clausse M; Filleul B; Marcelis L; Honhon B; D'Hondt L; Dopchie C; Verschaeve V; Duck L; Verhoeven D; Jousten P; Bonny MA; Moxhon AM; Tombal B; Kerger J
J Clin Oncol; 2008 Nov; 26(32):5261-8. PubMed ID: 18794543
[TBL] [Abstract][Full Text] [Related]
14. Randomized phase II trial of Custirsen (OGX-011) in combination with docetaxel or mitoxantrone as second-line therapy in patients with metastatic castrate-resistant prostate cancer progressing after first-line docetaxel: CUOG trial P-06c.
Saad F; Hotte S; North S; Eigl B; Chi K; Czaykowski P; Wood L; Pollak M; Berry S; Lattouf JB; Mukherjee SD; Gleave M; Winquist E;
Clin Cancer Res; 2011 Sep; 17(17):5765-73. PubMed ID: 21788353
[TBL] [Abstract][Full Text] [Related]
15. Combination of docetaxel, estramustine phosphate, and zoledronic acid in androgen-independent metastatic prostate cancer: efficacy, safety, and clinical benefit assessment.
Efstathiou E; Bozas G; Kostakopoulos A; Kastritis E; Deliveliotis C; Antoniou N; Skarlos D; Papadimitriou C; Dimopoulos MA; Bamias A
Urology; 2005 Jan; 65(1):126-30. PubMed ID: 15667877
[TBL] [Abstract][Full Text] [Related]
16. The Canadian Uro-Oncology Group multicentre phase II study of docetaxel administered every 3 weeks with prednisone in men with metastatic hormone-refractory prostate cancer progressing after mitoxantrone/prednisone.
Saad F; Ruether D; Ernst S; North S; Cheng T; Perrotte P; Karakiewicz P; Winquist E;
BJU Int; 2008 Aug; 102(5):551-5. PubMed ID: 18510661
[TBL] [Abstract][Full Text] [Related]
17. Platelet-derived growth factor receptor inhibition and chemotherapy for castration-resistant prostate cancer with bone metastases.
Mathew P; Thall PF; Bucana CD; Oh WK; Morris MJ; Jones DM; Johnson MM; Wen S; Pagliaro LC; Tannir NM; Tu SM; Meluch AA; Smith L; Cohen L; Kim SJ; Troncoso P; Fidler IJ; Logothetis CJ
Clin Cancer Res; 2007 Oct; 13(19):5816-24. PubMed ID: 17908974
[TBL] [Abstract][Full Text] [Related]
18. Association of rash with outcomes in a randomized phase II trial evaluating cetuximab in combination with mitoxantrone plus prednisone after docetaxel for metastatic castration-resistant prostate cancer.
Fleming MT; Sonpavde G; Kolodziej M; Awasthi S; Hutson TE; Martincic D; Rastogi A; Rousey SR; Weinstein RE; Galsky MD; Berry WR; Wang Y; Boehm KA; Asmar L; Rauch MA; Beer TM
Clin Genitourin Cancer; 2012 Mar; 10(1):6-14. PubMed ID: 22340631
[TBL] [Abstract][Full Text] [Related]
19. A phase I/II dose-escalation study of exisulind and docetaxel in patients with hormone-refractory prostate cancer.
Ryan CW; Stadler WM; Vogelzang NJ
BJU Int; 2005 May; 95(7):963-8. PubMed ID: 15839914
[TBL] [Abstract][Full Text] [Related]
20. A randomized study of docetaxel and dexamethasone with low- or high-dose estramustine for patients with advanced hormone-refractory prostate cancer.
Nelius T; Klatte T; Yap R; Kalinski T; Röpke A; Filleur S; Allhoff EP
BJU Int; 2006 Sep; 98(3):580-5. PubMed ID: 16925757
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]